You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華康生物醫學(08622.HK)年度淨虧擴大至1162.7萬元
格隆匯 03-25 06:29

格隆匯 3 月 25日丨華康生物醫學(08622.HK)發佈截至2020年12月31日止年度的年度業績公吿,集團該年度的收益同比減少約13.7%至約人民幣2196.7萬元。收益減少主要由於中國的生物製劑銷售額減少約人民幣440萬元所致。

報吿期內,集團錄得毛利約人民幣1471.8萬元,同比減少約17.9%。集團的毛利率保持相對穩定,該年度為約67.0%,而上年度的毛利率為約70.2%。年內公司擁有人應占虧損約人民幣1162.7萬元,上年同期公司擁有人應占虧損約人民幣28.4萬元。基本及攤薄每股虧損人民幣2.91分。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account